Yesterday it was reported that the SVP, Alks Inc; CFO ALKS of Alkermes (ALKS), James Frates, exercised options to buy 20,000 ALKS shares at $11.74 a share, for a total transaction value of $234.8K.
Following this transaction James Frates’ holding in the company was increased by 10.31% to a total of $4.58 million.
See today’s analyst top recommended stocks >>
The company has a one-year high of $45.16 and a one-year low of $19.36.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alkermes Plc IS a biopharmaceutical company, which engages in the development, research, and commercialization of medicines that are designed to address unmet medical needs of patients in major therapeutic areas. Its products include the brands Aristada and Vivitrol. The company was founded on May 4, 2011 and is headquartered in Dublin, Ireland.
